GLP-1 Picks and Shovels
NickyAds@nickyads
+3.5%
since Oct 1
The idea
I believe GLP-1 drugs reshape food, retail, and healthcare over the next decade, but the drugmakers themselves are too crowded to be the edge. Instead this basket owns the supply chain that gets paid regardless of whose drug wins: bioprocessing tools, manufacturing capacity, distribution, packaging, and ingredients, tilted to stay relevant whether the future is needles or pills. A small injectable-maker slice hedges that shift, with the rest spread across large-cap ballast and smaller asymmetric bets, plus a modest cash reserve.
What it owns
- Equipment and instruments that manufacture and quality-check GLP-1 drugs get deployed whether the market goes pills or pens. · DanaherIt supplies the bioprocessing equipment and consumables that every GLP-1 production run depends on, earning across formats., RepligenIt supplies the purification consumables used in every GLP-1 production run, earning on manufacturing volume growth across formats., Waters CorporationIt makes the analytical instruments that verify GLP-1 purity and dosage in every batch, oral or injectable., Agilent TechnologiesIts analytical instruments test and characterize GLP-1 drugs through development and manufacturing, earning on pharma lab spending., Mettler-ToledoIts precision instruments sit in nearly every GLP-1 plant and lab, earning as production capacity expands., AvantorIt supplies the chemicals and materials that GLP-1 plants and labs use daily, earning on total production and research activity.30%
- Drug distributors take a cut of every GLP-1 prescription filled, collecting tolls on volume growth independent of which format wins. · McKessonIt distributes the largest volume of GLP-1 prescriptions in America, collecting a margin on every shipment regardless of format., CencoraIt is the second major GLP-1 distributor, earning a cut on volume growth as prescriptions move through the distribution network., Cardinal HealthIt is one of the three major GLP-1 distributors, collecting a margin on prescription volume growth.19%
- Contract manufacturers and testing labs earn on every GLP-1 dose made, regardless of format, as long as outsourced production stays the norm. · Thermo Fisher ScientificIt manufactures GLP-1 drugs for outside customers and earns per batch made, staying profitable as long as drugmakers outsource rather than build in-house., Charles River LaboratoriesIt conducts the safety testing and preclinical work behind new GLP-1 programs, earning on the breadth of the pipeline across formats.14%
- Injectable pens and their components stay profitable as long as absolute injection volumes keep rising, even if pills capture growing share. · Becton DickinsonIt manufactures syringes and injection devices at unmatched scale, staying profitable as injectable GLP-1 volumes grow in absolute terms., West Pharmaceutical ServicesIt makes the rubber stoppers and components inside GLP-1 injector pens, earning as long as injectable volumes keep rising., Stevanato GroupIt manufactures the glass cartridges inside GLP-1 pens, staying profitable as injectable volume keeps growing.13%
- Blister packs and oral delivery systems earn as GLP-1 pills capture share and require more inactive ingredients per patient than injectables. · AptarGroupIt builds drug delivery and dispensing systems across formats, earning as total GLP-1 delivery volume expands., AmcorIt makes the blister packs that oral GLP-1 pills ship in, so its volume growth tracks pill adoption.9%
- Peptide synthesis methods and oral tablet excipients become the raw-material constraint as GLP-1 production volumes scale. · AshlandIt supplies the inactive ingredients that turn GLP-1 compounds into working tablets, so its earnings track oral pill adoption., CodexisIts enzymatic peptide synthesis method could capture share as GLP-1 makers pursue cheaper, cleaner manufacturing at massive scale.7%
- Cash8%